You Took Truvada to Help Protect Against HIV, Not Increase Your Risk of Kidney or Bone Problems.

You May Have Serious Legal Options. Contact Us to Learn More.

Contact us today. There’s no cost to talk to us about your legal options.

If you suffered from bone density issues or kidney failure after taking Truvada or another HIV medication such as Atripla, Complera, Stibild or Viread, it’s time to stand up and tell the manufacturer that this was NOT okay.

  • Want to stay in the know about important information to help protect your future? Simply subscribe to our newsletter!
  • This field is for validation purposes and should be left unchanged.

Truvada Lawsuit

Corporate Greed Wins Again.

Even Though the Company Was Working on a Safer Alternative to Truvada, They Chose to Withhold it From the Market.

It’s a story we’ve all heard a thousand times. A sad, but true, story, about a drug that was created to help prevent and treat HIV. In fact, Truvada was one of the first drugs specifically created to help prevent HIV (known as PreEp). It was a great concept, but it came with an increased risk of bone density or kidney problems. As a preventative treatment, Truvada had the potential to make a substantial amount of money (not to mention a high price tag.) And when it comes to a corporate bottom line, endangering that potentially “very profitable” drug isn’t an option. Ever.

Enter a newer HIV medication Gilead was also developing, called tenofovir alafenamide (TAF). Though this drug was likely known to NOT carry same the baggage as Truvada, primarily the kidney problems and bone density issues, its clinical testing, submission to the FDA for approval, etc. was dramatically delayed by the company until their Truvada patent was about to expire. This would allow the company to better control the HIV medication market and most importantly, protect their profits.

Truvada isn’t the only HIV medication tied to potential health problems. Other similar drugs include:

Atripla, Complera, Stibild and Viread

Truvada Was A “Safe” Way to Help Prevent HIV

When Truvada and other similar HIV medications came onto the U.S. market in 2001, Gilead led patients to believe these antiviral medications were safe to take. And more importantly, taking Truvada was a smart way to help protect yourself from HIV. What patients weren’t told was that Truvada could cause an increased risk of bone density problems and kidney failure.

A 2012 study conducted by doctors at the University of California – San Francisco (UCSF) found that the risk of chronic kidney disease increased by 33% each year that a patient took Truvada.

In response, a Gilead executive told the Wall Street Journal that the study “overstates some of the risks.”

If you were you prescribed Truvada, Atripla, Complera, Stibild or Viread when other equally effective medications without potentially dangerous side effects could have been taken, it is not okay.

If you were you prescribed Truvada, Atripla, Complera, Stibild or Viread when other equally effective medications without potentially dangerous side effects could have been taken, it is not okay.

Contact Us to Learn More

Six FDA Warnings Weren’t Enough?

Since 2002, Truvada manufacturer Gilead has received six warnings from the FDA for marketing the drug as “safe” and failing to mention the increased risks of kidney failure or bone density problems.

Kidney Warnings:

March 14, 2002 : The drug company was told it was not okay to have made oral statements claiming the drug was not toxic and did not pose a risk of kidney failure, despite the fact that Truvada kidney failure had been documented through clinical research and was included on the drug’s warning label.

July 29, 2003: The second letter repeated the 2002 warning and called for a more definitive response from Gilead. The company’s sales representatives had once again downplayed the increased risk of kidney failure from Truvada and promoted the drug for non-approved uses.

June 27, 2014: This third warning disapproved of a web link that promoted the drug’s safety and failed to mention the risk of kidney problems. The FDA made Gilead remove the link.

Bone Density Warnings:

March 14, 2002: The FDA called out Gilead due to its representatives making false and misleading statements. The sales representatives stated the drug had “no toxicities,” was “extremely safe,” “extremely well-tolerated,” and a “miracle drug” – making no mention of Truvada bone problems, despite bone fractures risks being documented and included on the drug’s warning label.

July 29, 2003: The same warning was reiterated from 2002: sales representatives were downplaying Truvada bone risks and promoting the drug for a broader-than-approved use.

June 27, 2014: The FDA issued a third warning that required the drug maker to remove a sponsored link that omitted information about bone problems from Truvada use.

Learn More

A question of timing: A lawsuit claims Gilead Sciences could have developed a less harmful version of its HIV treatment sooner…

–– Los Angeles Times, May 29, 2016.